Recent discussions on X about CRISPR Therapeutics (CRSP) have centered around the company’s latest quarterly results, which missed both revenue and earnings expectations. This shortfall has triggered a notable sell-off, with many expressing concerns over the pace of commercialization for their gene therapy, CASGEVY, despite its steady progress. The conversation reflects a mix of disappointment and cautious hope as some highlight the groundbreaking potential of their gene-editing technology.
Additionally, there’s attention on the company’s robust pipeline, with a few voices on X noting positive analyst updates, including raised price targets due to long-term growth prospects. Others remain skeptical, pointing to short-term execution challenges as a critical hurdle. The dialogue underscores the high stakes and intense scrutiny surrounding this innovative biotech firm.
Note: This discussion summary was generated from an AI condensation of post data.
CRISPR Therapeutics Insider Trading Activity
CRISPR Therapeutics insiders have traded $CRSP stock on the open market 22 times in the past 6 months. Of those trades, 4 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $CRSP stock by insiders over the last 6 months:
- SIMEON GEORGE has made 3 purchases buying 989,812 shares for an estimated $51,499,918 and 0 sales.
- SAMARTH KULKARNI (Chief Executive Officer) has made 0 purchases and 6 sales selling 61,394 shares for an estimated $3,050,070.
- JAMES R. KASINGER (General Counsel and Secretary) has made 0 purchases and 5 sales selling 18,693 shares for an estimated $920,052.
- JOHN GREENE purchased 7,000 shares for an estimated $313,947
- RAJU PRASAD (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,959 shares for an estimated $247,833.
- JULIANNE BRUNO (Chief Operating Officer) has made 0 purchases and 4 sales selling 3,435 shares for an estimated $147,300.
- NAIMISH PATEL (Chief Medical Officer) sold 3,932 shares for an estimated $141,316
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CRISPR Therapeutics Hedge Fund Activity
We have seen 170 institutional investors add shares of CRISPR Therapeutics stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 2,670,405 shares (-30.5%) from their portfolio in Q1 2025, for an estimated $90,873,882
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,262,560 shares (+182.9%) to their portfolio in Q1 2025, for an estimated $42,964,916
- TWO SIGMA INVESTMENTS, LP added 882,887 shares (+288.3%) to their portfolio in Q1 2025, for an estimated $30,044,644
- BALYASNY ASSET MANAGEMENT L.P. removed 810,468 shares (-90.7%) from their portfolio in Q1 2025, for an estimated $27,580,226
- MORGAN STANLEY added 804,980 shares (+162.6%) to their portfolio in Q1 2025, for an estimated $27,393,469
- TWO SIGMA ADVISERS, LP added 712,400 shares (+840.1%) to their portfolio in Q1 2025, for an estimated $24,242,972
- BAKER BROS. ADVISORS LP removed 653,912 shares (-50.0%) from their portfolio in Q1 2025, for an estimated $22,252,625
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CRISPR Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $CRSP in the last several months. We have seen 9 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 07/22/2025
- Piper Sandler issued a "Overweight" rating on 06/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/27/2025
- JMP Securities issued a "Market Outperform" rating on 06/27/2025
- Needham issued a "Buy" rating on 06/26/2025
- Chardan Capital issued a "Buy" rating on 06/26/2025
- Citigroup issued a "Buy" rating on 02/18/2025
To track analyst ratings and price targets for CRISPR Therapeutics, check out Quiver Quantitative's $CRSP forecast page.
CRISPR Therapeutics Price Targets
Multiple analysts have issued price targets for $CRSP recently. We have seen 15 analysts offer price targets for $CRSP in the last 6 months, with a median target of $78.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $42.0 on 08/05/2025
- Geoff Meacham from B of A Securities set a target price of $78.0 on 07/22/2025
- Gil Blum from Needham set a target price of $81.0 on 07/08/2025
- Edward Tenthoff from Piper Sandler set a target price of $105.0 on 06/27/2025
- Bill Maughan from Clear Street set a target price of $45.0 on 06/27/2025
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $65.0 on 06/27/2025
- Silvan Tuerkcan from JMP Securities set a target price of $86.0 on 06/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
